Outlook Therapeutics (OTLK) Interest Expenses (2015 - 2023)

Outlook Therapeutics (OTLK) has 8 years of Interest Expenses data on file, last reported at $206.0 in Q3 2023.

• Interest Expenses for Q3 2023 came in at $206.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $206.0 (down 32.01% YoY), and the FY2024 annual result was $3.2 million, up 24.72% from the prior year.
• Interest Expenses eased to $206.0 in Q3 2023 per OTLK's latest filing, from $303.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $1.1 million in Q2 2019 and troughed at $206.0 in Q3 2023.
• A 4-year average of $410262.8 and a median of $250409.0 in 2021 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2019 and 2020: Interest Expenses surged 126.64% in 2019, then sank 90.95% in 2020.
• A 4-year view of Interest Expenses shows it stood at $597665.0 in 2019, then plunged by 73.29% to $159663.0 in 2020, then jumped by 56.84% to $250409.0 in 2021, then tumbled by 99.92% to $206.0 in 2023.
• Business Quant data shows OTLK's Interest Expenses at $206.0 in Q3 2023, $303.0 in Q2 2023, and $250409.0 in Q1 2021.